Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

2.91
+0.22008.18%
Post-market: 2.84-0.0700-2.41%19:39 EDT
Volume:520.73K
Turnover:1.43M
Market Cap:503.43M
PE:-8.23
High:2.98
Open:2.67
Low:2.57
Close:2.69
52wk High:4.20
52wk Low:0.9100
Shares:173.00M
Float Shares:139.65M
Volume Ratio:1.10
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3536
EPS(LYR):-0.2476
ROE:-138.92%
ROA:-45.98%
PB:69.29
PE(LYR):-11.75

Loading ...

Entera Bio Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Dow Jones
·
Aug 08

Entera Bio Says Phase 2 Post-Hoc Analysis Supports Anabolic Effect of Oral EB613 in High-Risk Postmenopausal Osteoporosis Patients

Reuters
·
Aug 04

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

GlobeNewswire
·
Aug 04

Entera Bio Ltd Expected to Post a Loss of 8 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Entera Bio CEO Joins Canaccord Genuity Annual Growth Conference Fireside Chat

Reuters
·
Aug 01

NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am

Reuters
·
Jul 27

Entera Bio Prices USD 275 Million Private Placement at USD 2.04 Per Share

Reuters
·
Jul 27

Entera Bio Leads Our Top 3 Penny Stocks To Consider

Simply Wall St.
·
Jul 22

Entera Bio Shareholders Approve Authorized Share Increase at Annual Meeting

Reuters
·
Jul 17

America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX)

TIPRANKS
·
Jul 08

3 Promising Penny Stocks With Market Caps Under $600M

Simply Wall St.
·
Jun 23

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:17 PM

Reuters
·
Jun 23

Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback

MT Newswires Live
·
Jun 22

Entera Bio gets FDA backing for 12-month Phase 3 EB613 osteoporosis trial in 750 women

Reuters
·
Jun 22

After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?

TIPRANKS
·
Jun 18

Entera Bio and Opko Health present preclinical data for oral peptides

TIPRANKS
·
Jun 16

Entera Bio reports preclinical EB612 data, targets late-2026 IND filing for hypoparathyroidism program

Reuters
·
Jun 16

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

GlobeNewswire
·
Jun 16

Entera Bio reports Phase 1 data showing single-tablet EB613 matches Forteo PK/PD profile

Reuters
·
Jun 15